Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02176473 · ClinicalTrials.gov registry record · NA

Computerized Cognitive Behavioral Therapy and Electroconvulsive Therapy

A NA study, sponsored by Yale University.

Completed
Registry status
NA
Development phase
30
Enrollment target

NCT02176473: Completed NA study, sponsored by Yale University.

NCT02176473 is a NA study that has completed, run by Yale University. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02176473, a NA study, has completed, sponsored by Yale University.

COMPLETED
Registry status
NA
Development phase
30 participants
Enrollment target

Study Summary

In an open-label feasibility study, fifteen will be recruited to participate in the study from among those who have already chosen of their own accord to undergo ECT (standard of care) at Yale Psychiatric Hospital for treatment of a depressive episode. These patients will receive computer-assisted cognitive behavior therapy (CCBT).

Primary Outcome

The Beck Depression Inventory (BDI) is a 21-item, self-report rating inventory that measures characteristic attitudes and symptoms of depression . The treatment group will undergo depression rating scales (as well as cognitive screening) at baseline, at 2 weeks during their index course of ECT, following the completion of the ECT phase, and then every 5 weeks for a total of 25 weeks total after the completion of the ECT phase. Depression rating scales will include the BDI, QIDS-SR, MADRS, CGI,

Interventions

  • BEHAVIORAL Computerized Cognitive Behavioral Therapy

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2014-06
Est. Completion 2016-12
Phase NA
Yale University

1,492 total trials

What the finished NCT02176473 record still lists

NCT02176473 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).

The record links to 0 conditions, and to 1 intervention - of which Computerized Cognitive Behavioral Therapy is the first listed.

NCT02176473 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02176473 about?

NCT02176473 is a clinical study titled "Computerized Cognitive Behavioral Therapy and Electroconvulsive Therapy". In an open-label feasibility study, fifteen will be recruited to participate in the study from among those who have already chosen of their own accord to undergo ECT (standard of care) at Yale Psychiatric Hospital for treatment of a depressive episode. These patients will receive computer-assisted c...

What is the current status of trial NCT02176473?

This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2014-06. Estimated completion is 2016-12.

What interventions are being tested in trial NCT02176473?

The interventions under investigation include: Computerized Cognitive Behavioral Therapy (BEHAVIORAL).

Who is sponsoring clinical trial NCT02176473?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02176473's enrollment target sits among peer trials

30 1593rd of 2000 higher than 299 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02176473, the US trial registry maintained by the National Library of Medicine. NCT02176473 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.